Youth cancer research – CanTeen calls for expressions of interest

August 15, 2017

CanTeen is calling for expressions of interest from researchers, research organisations and other stakeholders who would like to apply for full or part funding for a project that will improve outcomes for young cancer patients.

It comes after the Australian Government provided $5 Million in funding to CanTeen via the Medical Research Future Fund (MRFF) for the Australian Young Cancer Patient Clinical Trials Initiative.

This new, targeted clinical research investment for adolescents and young adults (AYA) with cancer will facilitate novel clinical research activity and provide greater access to innovative and cutting edge treatment approaches for AYA cancer patients.

Funding will be offered to support clinical research targeting or substantially including adolescent and young adult cancer patients, including trials of new treatments for young cancer patients at highest risk of poor outcomes.

In addition to this funding opportunity, key program outcomes will include:

  • identifying new strategies to remove barriers to adolescent and young adult clinical trial participation such as age barriers, improved collaboration, access across paediatric and adult settings and trial referral pathways.
  • providing capacity across the Youth Cancer Services to assist with trial recruitment and patient navigation of the trial enrolment and participation process.

The application form is available online and the call for applications closes at midnight on Sunday 27 August 2017.

Every year, around 1,100 young people aged 15-25 are diagnosed with cancer and about 150 will die from the disease.

Brain cancer, sarcomas (bone and soft tissue cancers) and blood cancer (leukaemia) account for more than 60% of all cancer deaths among young Australians.

For more information about this funding opportunity or the Australian Young Cancer Patient Clinical Trials Initiative, please contact Dr Adam Walczak, Youth Cancer Services and Clinical Trials Manager.

Media contact: For more information or interviews, contact Kerry Kalcher on 02 9007 0208 / 0405 283 352.